Yongqiang Hua

947 total citations
28 papers, 693 citations indexed

About

Yongqiang Hua is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Yongqiang Hua has authored 28 papers receiving a total of 693 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 10 papers in Molecular Biology and 8 papers in Cancer Research. Recurrent topics in Yongqiang Hua's work include Pancreatic and Hepatic Oncology Research (12 papers), Hepatocellular Carcinoma Treatment and Prognosis (6 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (5 papers). Yongqiang Hua is often cited by papers focused on Pancreatic and Hepatic Oncology Research (12 papers), Hepatocellular Carcinoma Treatment and Prognosis (6 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (5 papers). Yongqiang Hua collaborates with scholars based in China and Japan. Yongqiang Hua's co-authors include Zhen Chen, Zhiqiang Meng, Zhouyu Ning, Luming Liu, Lianyu Chen, Weidong Shi, Hao Chen, Peng Wang, Song Gao and Tao Liu and has published in prestigious journals such as Journal of Clinical Oncology, Frontiers in Immunology and Life Sciences.

In The Last Decade

Yongqiang Hua

25 papers receiving 690 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yongqiang Hua China 16 434 346 200 78 77 28 693
Jiaming Huang China 17 518 1.2× 433 1.3× 216 1.1× 89 1.1× 81 1.1× 51 932
Zhiqing Fang China 14 285 0.7× 213 0.6× 124 0.6× 89 1.1× 49 0.6× 30 587
Xiqiang Cai China 11 385 0.9× 225 0.7× 154 0.8× 71 0.9× 31 0.4× 14 616
Yanmei Zou China 15 384 0.9× 253 0.7× 218 1.1× 53 0.7× 108 1.4× 35 680
Qingqu Guo China 14 326 0.8× 146 0.4× 247 1.2× 92 1.2× 84 1.1× 27 613
Zhizhen Dong China 16 450 1.0× 309 0.9× 174 0.9× 47 0.6× 156 2.0× 46 763
Hongmei Yong China 18 601 1.4× 273 0.8× 233 1.2× 54 0.7× 81 1.1× 41 878
Maria G. Pilo Germany 16 460 1.1× 339 1.0× 84 0.4× 101 1.3× 109 1.4× 20 713
Xuelong Jiao China 18 442 1.0× 295 0.9× 279 1.4× 201 2.6× 96 1.2× 43 926
Xianghong Yang China 16 353 0.8× 153 0.4× 290 1.4× 117 1.5× 54 0.7× 35 719

Countries citing papers authored by Yongqiang Hua

Since Specialization
Citations

This map shows the geographic impact of Yongqiang Hua's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yongqiang Hua with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yongqiang Hua more than expected).

Fields of papers citing papers by Yongqiang Hua

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yongqiang Hua. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yongqiang Hua. The network helps show where Yongqiang Hua may publish in the future.

Co-authorship network of co-authors of Yongqiang Hua

This figure shows the co-authorship network connecting the top 25 collaborators of Yongqiang Hua. A scholar is included among the top collaborators of Yongqiang Hua based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yongqiang Hua. Yongqiang Hua is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Zong, Shaoqi, Yifan Yang, Zifei Yin, et al.. (2025). Efficacy of therapies for intermediate-stage hepatocellular carcinoma: systematic review and network meta-analysis. Frontiers in Immunology. 16. 1577614–1577614.
3.
4.
Ning, Zhouyu, Ying Zhu, Lin Xie, et al.. (2024). Exploring the efficacy and safety of drug-eluting beads transarterial chemoembolization in pancreatic cancer liver metastasis. British Journal of Radiology. 97(1157). 1010–1015.
5.
Wang, Feng, Xiaogang Yan, Yongqiang Hua, et al.. (2023). PI3K/AKT/mTOR pathway and its related molecules participate in PROK1 silence-induced anti-tumor effects on pancreatic cancer. Open Life Sciences. 18(1). 20220538–20220538. 2 indexed citations
6.
Ning, Zhouyu, Lin Xie, Yongqiang Hua, et al.. (2023). Transarterial chemoembolization plus lenvatinib with or without a PD-1 inhibitor for advanced and metastatic intrahepatic cholangiocarcinoma: a retrospective real-world study. British Journal of Radiology. 96(1150). 20230079–20230079. 4 indexed citations
7.
Hua, Yongqiang, Ke Zhang, Jie Sheng, et al.. (2021). NUCB1 Suppresses Growth and Shows Additive Effects With Gemcitabine in Pancreatic Ductal Adenocarcinoma via the Unfolded Protein Response. Frontiers in Cell and Developmental Biology. 9. 641836–641836. 22 indexed citations
8.
Hua, Yongqiang, Ke Zhang, Jie Sheng, et al.. (2021). Fam83D promotes tumorigenesis and gemcitabine resistance of pancreatic adenocarcinoma through the Wnt/β-catenin pathway. Life Sciences. 287. 119205–119205. 27 indexed citations
9.
Shi, Weidong, Chenyue Zhang, Zhouyu Ning, et al.. (2021). CMTM8 as an LPA1-associated partner mediates lysophosphatidic acid-induced pancreatic cancer metastasis. Annals of Translational Medicine. 9(1). 42–42. 16 indexed citations
10.
Shi, Weidong, Lanyun Feng, Shu Dong, et al.. (2020). FBXL6 governs c-MYC to promote hepatocellular carcinoma through ubiquitination and stabilization of HSP90AA1. Cell Communication and Signaling. 18(1). 100–100. 58 indexed citations
11.
Shi, Weidong, Lanyun Feng, Shu Dong, et al.. (2020). Exploration of prognostic index based on immune-related genes in patients with liver hepatocellular carcinoma. Bioscience Reports. 40(7). 6 indexed citations
12.
13.
Hua, Yongqiang, Lianyu Chen, Caijun Wu, et al.. (2019). Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer. Journal of Translational Medicine. 17(1). 30–30. 73 indexed citations
14.
Shi, Weidong, Chenyue Zhang, Zhouyu Ning, et al.. (2019). Long non-coding RNA LINC00346 promotes pancreatic cancer growth and gemcitabine resistance by sponging miR-188-3p to derepress BRD4 expression. Journal of Experimental & Clinical Cancer Research. 38(1). 60–60. 59 indexed citations
15.
Hua, Yongqiang, Yaodong Zhu, Jijie Zhang, et al.. (2018). miR-122 Targets X-Linked Inhibitor of Apoptosis Protein to Sensitize Oxaliplatin-Resistant Colorectal Cancer Cells to Oxaliplatin-Mediated Cytotoxicity. Cellular Physiology and Biochemistry. 51(5). 2148–2159. 34 indexed citations
16.
Yan, Xiaogang, Yongqiang Hua, Liya Huang, et al.. (2018). EG-VEGF silencing inhibits cell proliferation and promotes cell apoptosis in pancreatic carcinoma via PI3K/AKT/mTOR signaling pathway. Biomedicine & Pharmacotherapy. 109. 762–769. 25 indexed citations
17.
Zheng, Peiyong, et al.. (2016). Clinical and psychometric validation of the quality of life assessment system for advanced gastric cancer based on traditional Chinese medicine. Chinese Journal of Integrative Medicine. 22(8). 581–588. 6 indexed citations
18.
Gao, Song, et al.. (2016). Nanog Predicts Poor Prognosis in Human Pancreatic Cancer and Is Downregulated by QingyihuaJi Formula in Pancreatic Cancer Stem Cells. Evidence-based Complementary and Alternative Medicine. 2016(1). 7028289–7028289. 5 indexed citations
19.
Shi, Weidong, Zhiqiang Meng, Zhen Chen, et al.. (2011). RNA interference against MDM2 suppresses tumor growth and metastasis in pancreatic carcinoma SW1990HM cells. Molecular and Cellular Biochemistry. 387(1-2). 1–8. 15 indexed citations
20.
Xing, Lianjun, Li Zhang, Tao Liu, et al.. (2011). Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver. European Journal of Pharmacology. 668(3). 467–471. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jiaming Huang Breakdown of academic impact, for papers by Zhiqing Fang Breakdown of academic impact, for papers by Xiqiang Cai Breakdown of academic impact, for papers by Yanmei Zou Breakdown of academic impact, for papers by Qingqu Guo Breakdown of academic impact, for papers by Zhizhen Dong Breakdown of academic impact, for papers by Hongmei Yong Breakdown of academic impact, for papers by Maria G. Pilo Breakdown of academic impact, for papers by Xuelong Jiao Breakdown of academic impact, for papers by Xianghong Yang
Rankless by CCL
2026